



Argos Therapeutics
Investor Relations Department
4233 Technology Drive
Durham, NC 27704
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARG5


Last Trade:	0.20
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.13 - 5.68
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 11, 2017*
[Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting](#)
- Nov 9, 2017*
[Argos Reports Third Quarter 2017 Financial Results and Operational Highlights](#)
- Nov 6, 2017*
[Argos Announces Receipt of Milestone Payment from Lummy \(Hong Kong\) Co. Ltd.](#)
- Nov 6, 2017*
[Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017](#)
- Sep 26, 2017*
[Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors](#)

Financials [\[View all \]](#)

- Mar 16, 2017*
[Annual Report \(10-K\)](#)
- Jul 6, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)